Stéphane Dalle

发表

Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study

M. Kersten, D. Maucort-Boulch, M. Jalali, 2023, BMJ Open.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, P. Ascierto, C. Blank, 2023, European journal of cancer.

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

P. Ascierto, R. Dummer, M. Del Vecchio, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of responses to immune checkpoint blockade in advanced melanoma

David M. Woods, Y. Koguchi, G. Kroemer, 2017, Nature Communications.

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

N. Khanafer, L. Thomas, G. Duru, 2018, BMC Cancer.

Hyperprogression in advanced melanoma is not restricted to immunotherapy

C. Lebbé, O. Dereure, L. Mortier, 2023, European Journal of Cancer.

Desmoplastic melanoma on the nose: electrochemotherapy as an alternative treatment to local advanced disease

J. Malvehy, S. Puig, L. Thomas, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Monoclonal antibodies in clinical oncology.

L. Thomas, C. Dumontet, S. Dalle, 2008, Anti-cancer agents in medicinal chemistry.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

C. Coens, A. van den Eertwegh, V. Atkinson, 2024, The Lancet. Oncology.

ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell

L. Barbollat-Boutrand, J. Caramel, Yaqi Tang, 2023 .

Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers

L. Zitvogel, C. Radulescu, M. Rouanne, 2023, Journal of Experimental & Clinical Cancer Research.